Patents by Inventor John S. Lollar
John S. Lollar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7012132Abstract: Specific amino acid loci of human factor VIII interact with inhibitory antibodies of hemophilia patients who have developed such antibodies after being treated with factor VIII. Modified factor VIII is disclosed in which the amino acid sequence is changed by a substitution at one or more of the specific loci. The modified factor VIII is not inhibited by inhibitory antibodies against the A2 or C2 domain epitopes. The modified factor VIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory antibodies.Type: GrantFiled: June 28, 2002Date of Patent: March 14, 2006Assignee: Emory UniversityInventor: John S. Lollar
-
Patent number: 6852537Abstract: A process is provided for expanding the population of endothelial cells obtained from peripheral blood which can be transformed with a vector comprising a DNA sequence encoding a preselected bioactive polypeptide. The resulting transgenic endothelial cells are useful to biocompatibilize implantable medical devices or can be used directly, as for gene therapy.Type: GrantFiled: May 24, 2001Date of Patent: February 8, 2005Assignee: Regents of the University of Minnesota Emory UniversityInventors: Robert P. Hebbel, Yi Lin, John S. Lollar
-
Publication number: 20040249134Abstract: Specific amino acid loci of human factor VIII interact with inhibitory antibodies of hemophilia patients after being treated with factor VIII. Modified factor VIII is disclosed in which the amino acid sequence is changed by a substitution at one or more of the specific loci. The modified factor VIII si useful for hemophiliacs, either to avoid or prevent the action of inhibitory antibodies.Type: ApplicationFiled: June 29, 2004Publication date: December 9, 2004Inventor: John S. Lollar
-
Patent number: 6770744Abstract: Specific amino acid loci of human factor VIII interact with inhibitory antibodies of hemophilia patients after being treated with factor VIII. Modified factor VIII is disclosed in which the amino acid sequence is changed by a substitution at one or more of the specific loci. The modified factor VIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory antibodies.Type: GrantFiled: September 19, 2001Date of Patent: August 3, 2004Assignee: Emory UniversityInventor: John S. Lollar
-
Patent number: 6759216Abstract: The development of inhibitory antibodies to blood coagulation factor VIII (fVIII) results in a severe bleeding tendency. These antibodies arise in patients with hemophilia A (hereditary fVIII deficiency) who have been transfused with fVIII. They also occur in non-hemophiliacs, which produces the condition acquired hemophilia. We describe a method to construct and express novel recombinant fVIII molecules which escape detection by existing inhibitory antibodies (low antigenicity fVIII) and which decrease the likelihood of developing inhibitory antibodies (low immunogenicity fVIII). In this method, fVIII is glycosylated at sites that are known to be antibody recognition sequences (epitopes). This produces the desired properties of low antigenicity fVIII and low (immunogenicity fVIII. The mechanism is similar to one used by viruses such as the AIDS virus, which glycosylates its surface proteins to escape detection by the immune system.Type: GrantFiled: November 5, 1999Date of Patent: July 6, 2004Assignee: Emory UniversityInventor: John S. Lollar
-
Publication number: 20030166536Abstract: Specific amino acid loci of human factor VIII interact with inhibitory antibodies of hemophilia patients who have developed such antibodies after being treated with factor VIII. Modified factor VIII is disclosed in which the amino acid sequence is changed by a substitution at one or more amino acids of positions 484-508 of the A2 domain. The modified factor VIII is useful as a clotting factor supplement for hemophiliacs.Type: ApplicationFiled: April 23, 2002Publication date: September 4, 2003Inventor: John S. Lollar
-
Publication number: 20030129174Abstract: Compositions and methods are provided for the in vivo gene delivery of nucleic acid sequences encoding the factor VIII protein to the liver endothelial sinusoidal cells (LSECs). Compositions and methods are also provided for the ex vivo gene transfer of nucleic acid sequences encoding the factor VIII protein to cultured LSECs and the implantation of the transformed LSECs in vivo. These methods and compositions increase the level of factor VIII in the blood stream and find use in the gene therapy treatment of hemophilia A.Type: ApplicationFiled: December 3, 2002Publication date: July 10, 2003Applicant: Emory UniversityInventors: John S. Lollar, Hung V. Do, John F. Healey, Edmund K. Waller
-
Publication number: 20030068785Abstract: Specific amino acid loci of human factor VIII interact with inhibitory antibodies of hemophilia patients who have developed such antibodies after being treated with factor VIII. Modified factor VIII is disclosed in which the amino acid sequence is changed by a substitution at one or more of the specific loci. The modified factor VIII is not inhibited by inhibitory antibodies against the A2 or C2 domain epitopes. The modified factor VIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory antibodies.Type: ApplicationFiled: June 28, 2002Publication date: April 10, 2003Inventor: John S. Lollar
-
Patent number: 6517830Abstract: Compositions and methods are provided for the in vivo gene delivery of nucleic acid sequences encoding the factor VIII protein to the liver endothelial sinusoidal cells (LSECs). Compositions and methods are also provided for the ex vivo gene transfer of nucleic acid sequences encoding the factor VIII protein to cultured LSECs and the implantation of the transformed LSECs in vivo. These methods and compositions increase the level of factor VIII in the blood stream and find use in the gene therapy treatment of hemophilia A.Type: GrantFiled: August 4, 2000Date of Patent: February 11, 2003Assignee: Emory UniversityInventors: John S. Lollar, Hung V. Do, John F. Healey, Edmund K. Waller
-
Publication number: 20020182670Abstract: Specific amino acid loci of human factor VIII interact with inhibitory antibodies of hemophilia patients after being treated with factor VIII. Modified factor VIII is disclosed in which the amino acid sequence is changed by a substitution at one or more of the specific loci. The modified factor VIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory antibodies.Type: ApplicationFiled: September 19, 2001Publication date: December 5, 2002Inventor: John S. Lollar
-
Patent number: 6458563Abstract: The invention relates to a modified B-domainless form of porcine factor VIII, to a DNA encoding the same, and to the use thereof for treatment of hemophilia.Type: GrantFiled: March 10, 2000Date of Patent: October 1, 2002Assignee: Emory UniversityInventor: John S. Lollar
-
Patent number: 6376463Abstract: Specific amino acid loci of human factor VIII interact with inhibitory antibodies of hemophilia patients who have developed such antibodies after being treated with factor VIII. Modified factor VIII is disclosed in which the amino acid sequence is changed by a substitution at one or more amino acids of positions 484-508 of the Az domain. The modified factor VIII is useful as a clotting factor supplement for hemophiliacs.Type: GrantFiled: May 20, 1999Date of Patent: April 23, 2002Assignee: Emory UniversityInventor: John S. Lollar
-
Publication number: 20020042130Abstract: A process is provided for expanding the population of endothelial cells obtained from peripheral blood which can be transformed with a vector comprising a DNA sequence encoding a preselected bioactive polypeptide. The resulting transgenic endothelial cells are useful to biocompatibilize implantable medical devices or can be used directly, as for gene therapy.Type: ApplicationFiled: May 24, 2001Publication date: April 11, 2002Applicant: Regents of the University of Minnesota and Emory UniversityInventors: Robert P. Hebbel, Yi Lin, John S. Lollar
-
Patent number: 6180371Abstract: Specific amino acid loci of human factor VIII interact with inhibitory antibodies of hemophilia patients who have developed such antibodies after being treated with factor VIII. Modified factor VIII is disclosed in which the amino acid sequence is changed by a substitution at one or more of the specific loci. The modified factor VIII is not inhibited by inhibitory antibodies against the A2 or C2 domain epitopes. The modified factor VIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory antibodies.Type: GrantFiled: March 10, 1998Date of Patent: January 30, 2001Assignee: Emory UniversityInventor: John S. Lollar
-
Patent number: 5888974Abstract: A hybrid procoagulant factor VIII is produced by isolation and recombination of human and other nonhuman mammalian factor VIII subunits or domains, or by genetic engineering of the human and animal factor VIII genes. Subunits or domains of factor VIII that have been purified from human or animal plasma are isolated, and hybrid human/animal factor VIII is produced by (1) mixing either animal heavy chain subunits with human light chain subunits or by mixing human heavy chain subunits with animal light chain subunits, thereby producing human light chain/animal heavy chain and human heavy chain/animal light chain hybrid molecules; or by (2) mixing one or more domains of one species with one or more domains of the other species. These hybrid molecules are isolated by ion exchange chromatography.Type: GrantFiled: June 7, 1995Date of Patent: March 30, 1999Assignee: Emory UniversityInventors: John S. Lollar, Marschall S. Runge
-
Patent number: 5859204Abstract: Site-specific replacement of amino acids in the region of positions 484-509 of human factor VIII can result in reduction of reactivity to an inhibitory antibody while procoagulant activity is retained. Modified human factor VIII having an immunoreactivity-reducing amino acid substituted for the naturally occurring amino acid is described.Type: GrantFiled: June 26, 1996Date of Patent: January 12, 1999Assignee: Emory UniversityInventor: John S. Lollar
-
Patent number: 5744446Abstract: Provided is a hybrid Factor VIII having a sequence of amino acids selected from the group of A2 domain fragments 373-540, 373-508, 445-508, 484-508, 404-508, 489-508 and 484-489 according to Seq ID NO 2 substituted with corresponding sequence of porcine or murine Factor VIII. Invention also relates to methods of treatment Factor VIII deficiency with said hybrid Factor VIII.Type: GrantFiled: June 7, 1995Date of Patent: April 28, 1998Assignee: Emory UniversityInventors: John S. Lollar, Marschall S. Runge
-
Patent number: 5663060Abstract: A hybrid human/animal coagulation factor VIII is produced by isolation and recombination of human and other non-human mammalian factor VIII subunits or domains, or by genetic engineering of the human and animal factor VIII genes. Subunits or domains of factor VIII that have been purified from human or animal plasma are isolated, and hybrid human/animal factor VIII is produced by (1) mixing either animal heavy chain subunits with human light chain subunits or by mixing human heavy chain subunits with animal light chain subunits, thereby producing human light chain/animal heavy chain and human heavy chain/animal light chain hybrid molecules; or by (2) mixing one or more domains of one species with one or more domains of the other species. These hybrid molecules are isolated by ion exchange chromatography.Type: GrantFiled: March 11, 1994Date of Patent: September 2, 1997Assignee: Emory UniversityInventors: John S. Lollar, Marschall S. Runge
-
Patent number: 5583209Abstract: A hybrid human/porcine coagulation factor VIII is produced by isolation and recombination of human and porcine factor VIII subunits, or by genetic engineering of the human and porcine factor VIII genes. Subunits of factor VIII that have been purified from human or porcine plasma are isolated, and hybrid human/porcine factor VIII is produced by mixing either porcine heavy chain subunits with human light chain subunits or by mixing human heavy chain subunits with porcine light chain subunits, thereby producing human light chain/porcine heavy chain and human heavy chain/porcine light chain hybrid molecules. These hybrid molecules are isolated by ion exchange chromatography. Alternatively, recombinant DNA methods are used to swap elements of porcine factor VIII for the corresponding elements of human factor VIII to produce hybrid human/porcine factor VIII.Type: GrantFiled: May 31, 1994Date of Patent: December 10, 1996Assignee: Emory UniversityInventors: John S. Lollar, Marschall S. Runge
-
Patent number: 5364771Abstract: A hybrid human/porcine coagulation factor VIII is produced by isolation and recombination of human and porcine factor VIII subunits, or by genetic engineering of the human and porcine factor VIII genes. Subunits of factor VIII that have been purified from human or porcine plasma are isolated, and hybrid human/porcine factor VIII is produced by mixing either porcine heavy chain subunits with human light chain subunits or by mixing human heavy chain subunits with porcine light chain subunits, thereby producing human light chain/porcine heavy chain and human heavy chain/porcine light chain hybrid molecules. These hybrid molecules are isolated by ion exchange chromatography. Alternatively, recombinant DNA methods are used to swap elements of porcine factor VIII for the corresponding elements of human factor VIII to produce hybrid human/porcine factor VIII.Type: GrantFiled: April 7, 1992Date of Patent: November 15, 1994Assignee: Emory UniversityInventors: John S. Lollar, Marschall S. Runge